Collateral damage: the conundrum of drug safety-Reference-Cited by-同舟云学术

Collateral damage: the conundrum of drug safety

Published:2009-08-18 Issue:10 Volume:52 Page:1975-1982
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Gale E. A. M.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00125-009-1491-8.pdf

Reference37 articles.

1. Torsoli A (2009) Sanofi shares slump; analysts cut ratings in Lantus. Available from http://www.bloomberg.com/apps/news?pid=20601085&sid=aEiby7t0.yXc , accessed 29 July 2009. I have verified the quote from a transcript of the call

2. Smith U, Gale EAM (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699–1708

3. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction. N Engl J Med 356:2457–2471

4. Nathan DM (2007) Finding new treatments for diabetes—how many, how fast, how good? N Engl J Med 356:437–440

5. Hauber A, Gale EAM (2006) The market in diabetes. Diabetologia 49:247–252

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Fenugreek, Cinnamon, Curcuma longa, Berberine and Momordica charantia in Type 2 Diabetes Mellitus Treatment: A Review;Pharmaceuticals;2023-03-30

2. Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials;Scientific Reports;2017-08-15

3. Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis;Rheumatology International;2014-09-17

4. Melanoma and non-Melanoma Skin Cancer in Inflammatory Bowel Disease Patients following Tumor Necrosis Factor-alpha Inhibitor Monotherapy and in Combination with Thiopurines: Analysis of the Food and Drug Administration Adverse Event Reporting System;J GASTROINTEST LIVER;2014

5. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease;Alimentary Pharmacology & Therapeutics;2014-08-28